comparemela.com

Latest Breaking News On - Johnw osborn - Page 1 : comparemela.com

Norman Charles Van Arsdalen, 96 - centraljersey com

Norman Charles Van Arsdalen, 96 - centraljersey com
centraljersey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from centraljersey.com Daily Mail and Mail on Sunday newspapers.

John W Osborn Jr - The Martha s Vineyard Times

John W. Osborn, Jr., 92, of Mechanicsburg, Pa., passed away on Friday, March 29, 2024, at Holy Spirit Hospital.  Born on August 13, 1931, in Oak Bluffs, he was the son of Elizabeth E. (House) and John W. Osborn Sr. John worked as a salesman for Powernail, as well as a sales manager for Inland Container […]

Thomas Martin Osborn

Warren, Pa. — Thomas Martin Osborn, 82, of Cobham Park Road, Warren, Pennsylvania, passed away at St. Vincent Hospital in Erie on June 18, 2023 after a brief illness.

BioSig Technologies : Annual report pursuant to Section 13 and 15(d)

Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023

BioSig s Division NeuroClear Technologies Signs a Research Agreement with the University of MinnesotaNeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease

Published: Dec 18, 2020 Westport, CT, Dec. 18, 2020 (GLOBE NEWSWIRE) BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota.  Under the terms of the agreement, the Company intends to launch a program to develop novel therapies to treat sympathetic nervous system disease. Due to launch in Q4 2020, the program studies are expected to form a foundation for developing a new platform technology to address disorders of the autonomic nervous system. NeuroClear intends to develop new intellectual properties and products, including new hardware, software, and algorithmic solutions, with the support of a tier 1 US-based manufacturing

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.